We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

MyFibroScan Screenshots

About MyFibroScan

Your everyday FibroScan® companion to access Interpretation Guide and Scores

FibroScan® is the non-invasive solution for comprehensive management of liver health.

Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.

myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.

Scores enhance Fibroscan® liver disease assessment with biological markers.

Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.

- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.

What's New in the Latest Version 2.4.0

Last updated on Nov 13, 2024

Update target Android version to run on Android 14

Translation Loading...

Additional APP Information

Latest Version

Request MyFibroScan Update 2.4.0

Uploaded by

August Murniy

Requires Android

Android 5.1+

Available on

Get MyFibroScan on Google Play

Show More
Languages
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.